11,040 Shares in Becton, Dickinson and Company $BDX Acquired by NBT Bank N.A.

Key Points

• NBT Bank acquired 11,040 shares of Becton, Dickinson and Company during the third quarter, valued at approximately $1.98 million. Institutional investors collectively own 86.97% of BDX, with BlackRock, State Street and First Eagle among significant holders.
• Analysts maintain a mixed outlook, resulting in a consensus “Hold” rating and an average price target of $185.07. The stock recently opened at $200.21, near its 12-month high of $200.47.
• BD reported quarterly EPS of $3.23, exceeding estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company declared a quarterly dividend of $1.05, equivalent to a 2.1% annual yield, although its payout ratio was elevated at 126.51%.

NBT Bank N.A. acquired a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,040 shares of the medical instruments supplier's stock, valued at approximately $1,976,000.

Other large investors have also modified their holdings of the company. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $3,721,533,000. State Street Corp boosted its stake in Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier's stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares during the period. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Bank of America Corp DE acquired a new stake in Becton, Dickinson and Company in the 2nd quarter valued at approximately $474,993,000. Finally, Legal & General Group Plc grew its holdings in Becton, Dickinson and Company by 1.5% in the 2nd quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier's stock valued at $318,050,000 after buying an additional 30,766 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Bank of America lifted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday, August 31st. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price for the company. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They issued an "outperform" rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and a consensus price target of $185.07.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $200.21 on Friday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47. The company has a market capitalization of $55.16 billion, a P/E ratio of 60.30, a P/E/G ratio of 13.10 and a beta of 0.21. The stock has a 50 day moving average of $185.10 and a two-hundred day moving average of $164.86. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company's stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,906 shares of company stock valued at $1,265,855 in the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.